by Marc Braunstein
Our latest committee member spotlight features Marc Braunstein, MD, PhD, FACP, FASCO, associate professor of medicine at NYU Grossman Long Island School of Medicine and fellowship program director...
by Blood Advances
Researchers report that following up brexucabtagene autoleucel (brexu-cel) treatment with tyrosine kinase inhibitor (TKI)-based maintenance therapy produces a survival benefit in adults with...
by Transplantation and Cellular Therapy
New evidence upholds bendamustine as a viable alternative to fludarabine in lymphodepleting (LD) chemotherapy ahead of chimeric antigen receptor (CAR) T-cell treatment.
by Leukemia
Recent study findings may offer clues into what kind of scenarios support or undermine chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of relapsed/refractory B-cell acute...
by Immunotherapy
Injection of chimeric antigen receptor (CAR) T cells into the brain effectively treats glioblastoma multiforme (GBM), a particularly aggressive type of brain tumor, but researchers say the effect...
by Alex Kadhim
A comprehensive review from the ASTCT–NMDP ACCESS Initiative highlights persistent disparities in access to hematopoietic cell transplantation and CAR T therapy, revealing how race, age,...